Dr. Reddy's Laboratories Limited (NSE:DRREDDY)
India · Delayed Price · Currency is INR 1,178.00
+5.40 (0.46%)
Aug 5, 2026, 3:15 PM IST
Dr. Reddy's Laboratories Revenue
Dr. Reddy's Laboratories had revenue of 80.71B INR in the quarter ending June 30, 2026, a decrease of -5.56%. This brings the company's revenue in the last twelve months to 175.82B, up 3.97% year-over-year. In the fiscal year ending March 31, 2026, Dr. Reddy's Laboratories had annual revenue of 335.93B with 3.19% growth.
Revenue (ttm)
175.82B
Revenue Growth
+3.97%
P/S Ratio
2.92
Revenue / Employee
12.03M
Employees
27,527
Market Cap
966.80B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 335.93B | 10.40B | 3.19% |
| Mar 31, 2025 | 325.54B | 46.37B | 16.61% |
| Mar 31, 2024 | 279.16B | 33.29B | 13.54% |
| Mar 31, 2023 | 245.88B | 31.49B | 14.69% |
| Mar 31, 2022 | 214.39B | 24.67B | 13.00% |
| Mar 31, 2021 | 189.72B | 15.12B | 8.66% |
| Mar 31, 2020 | 174.60B | 20.75B | 13.49% |
| Mar 31, 2019 | 153.85B | 11.82B | 8.32% |
| Mar 31, 2018 | 142.03B | 1.22B | 0.87% |
| Mar 31, 2017 | 140.81B | -13.90B | -8.98% |
| Mar 31, 2016 | 154.71B | 6.52B | 4.40% |
| Mar 31, 2015 | 148.19B | 16.02B | 12.12% |
| Mar 31, 2014 | 132.17B | 15.90B | 13.68% |
| Mar 31, 2013 | 116.27B | 19.53B | 20.19% |
| Mar 31, 2012 | 96.74B | 22.04B | 29.51% |
| Mar 31, 2011 | 74.69B | 4.42B | 6.28% |
| Mar 31, 2010 | 70.28B | 836.00M | 1.20% |
| Mar 31, 2009 | 69.44B | 19.44B | 38.87% |
| Mar 31, 2008 | 50.01B | -79.27B | -61.32% |
| Mar 31, 2007 | 129.28B | 80.94B | 167.42% |
| Mar 31, 2006 | 48.34B | 9.70B | 25.10% |
| Mar 31, 2005 | 38.65B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Aurobindo Pharma | 336.53B |
| Cipla | 280.68B |
| Zydus Lifesciences | 271.48B |
| Glenmark Pharmaceuticals | 177.37B |
| Mankind Pharma | 147.38B |
| Alkem Laboratories | 147.12B |
| Divi's Laboratories | 112.30B |
| Ipca Laboratories | 96.47B |
Dr. Reddy's Laboratories News
- 1 day ago - Dr. Reddy's Launches First-to-Market Generic Sugammadex Injection In The U.S - Nasdaq
- 1 day ago - Dr. Reddy's Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States - Business Wire
- 2 days ago - Dr Reddy’s registers PD-1 inhibitor for rare head and neck cancer in South Africa - The Times of India
- 4 days ago - Dr Reddy’s gets USFDA nod for Rituximab biosimilar - The Times of India
- 5 days ago - Dr. Reddy's Laboratories (RDY) Securities Investigation Notice - Levi & Korsinsky - PRNewsWire
- 7 days ago - Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Dr. Reddy's Laboratories (RDY) - GlobeNewsWire
- 8 days ago - RDY Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Dr. Reddy's Laboratories (RDY) - Business Wire
- 9 days ago - Thailand approves Nuzolvence antibiotic for gonorrhoea treatment - The Times of India